Fate Therapeutics

FATE Rare disease Lead: Phase 2 1 Biotech Distilled article ↓

Most recent annual filing: 2026-02-26

Catalyst timeline

FT839 Ph1 start2H 2026FT839 Ph1 start, 2H 2026, routine
FT819 Ph1 readout4Q 2026FT819 Ph1 readout, 4Q 2026, major
Autolus obe-cel CARLYSLE readout4Q 2026Autolus obe-cel CARLYSLE readout, 4Q 2026, material
Kyverna miv-cel BLA filing4Q 2026Kyverna miv-cel BLA filing, 4Q 2026, notable
FATE corporate updateNov 2026FATE corporate update, Nov 2026, routine
FATE financingNov 2026FATE financing, Nov 2026, routine
FT836 readout1H 2027FT836 readout, 1H 2027, notable
FT819 interim2H 2027FT819 interim, 2H 2027, material
FT819 enrollment done1H 2028FT819 enrollment done, 1H 2028, notable
Autolus obe-cel LUMINA readout2028Autolus obe-cel LUMINA readout, 2028, notable
FT819 toplineMay–Dec 2028FT819 topline, May–Dec 2028, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (10 active programs)

FT819

Cell Target: CD19

Systemic Lupus Erythematosus Phase 1 NCT06308978
Systemic Sclerosis Phase 1 NCT06308978
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Phase 1
Idiopathic Inflammatory Myositis Phase 1 NCT06308978
Lupus Nephritis Phase 2 NCT06308978

FT836

Cell Target: MICA, MICB, MICA/B

FT825

ONO-8250

Cell Target: HER2

Solid Tumors Phase 1 Ono Pharmaceutical NCT06241456

FT522

Cell Target: CD19, CD16, 4-1BB

Undisclosed indication Preclinical

FT839

Cell Target: CD19, CD38

Rheumatoid Arthritis Preclinical NCT07800871

Technology platforms

iPSC product platform

Induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapy platform combining multiplexed engineering of human iPSCs with single-cell selection to create clonal master iPSC lines for scalable manufacture of CAR T-cell and NK-cell products; focus areas include hematologic malignancies, solid tumors, and autoimmune diseases.

Sword and Shield

Novel alloimmune defense technology combining an alloimmune defense receptor (ADR) with CD58 knockout to enable CAR T-cell evasion of host alloreactive immune cells, designed to eliminate the need for conditioning chemotherapy; applied to iPSC-derived off-the-shelf CAR T-cell candidates in oncology and autoimmune diseases.

iPSC product platform · Ono Pharmaceutical

Induced pluripotent stem cell (iPSC) platform enabling production of off-the-shelf, multiplexed-engineered iPSC-derived cellular immunotherapies including CAR T-cell and CAR NK cell product candidates targeting solid tumor and hematologic disease antigens

Sword & Shield

Alloimmune Defense Receptor combined with CD58 knockout, designed to selectively eliminate and evade host allogeneic immune responses, promote functional persistence, and avoid need for conditioning chemotherapy in off-the-shelf iPSC-derived CAR T-cell therapies for autoimmune disease and hematologic malignancies

Discontinued (1)

FT522 — B-Cell Lymphoma · Phase 1 study in relapsed/refractory BCL completed enrollment; further development being evaluated in autoimmune indications

Biotech Distilled coverage (1)

2026-09-25 Fate Therapeutics (FATE) — Scientific Deep Dive for FT819, FT839 and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.